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Abstract. Cancer immunotherapy is a promising new approach 
to cancer treatment. It has been demonstrated that a high 
number of tumor-specific cytotoxic T cells (CTLs) is associ-
ated with increased disease-specific survival in lung cancer 
patients. Identification of superior CTL epitopes from tumor 
antigens is essential for the development of immunotherapy 
for malignant tumors. The EML4-ALK fusion gene was 
recently identified in a subset of non-small cell lung cancers 
(NSCLCs). In this study we searched for HLA-A*02:01- and 
HLA-A*24:02-restricted epitopes derived from EML4-ALK by 
screening predicted EML4-ALK-derived candidate peptides 
for the induction of tumor-reactive CTLs. Nine EML4-
ALK-derived peptides were selected by a computer algorithm 
based on a permissive HLA-A*02:01 or HLA-A*24:02 binding 
motif. One of the nine peptides induced peptide-specific CTLs 
from human peripheral blood mononuclear cells. We were 
able to generate a peptide-specific CTL clone. This CTL clone 
specifically recognized peptide-pulsed T2 cells and H2228 
cells expressing HLA-A*02:01 and EML4-ALK that had been 
treated with IFN-γ 48 h prior to examination. CTL activity was 
inhibited by an anti-HLA-class I monoclonal antibody (W6/32), 
consistent with a class I-restricted mechanism of cytotoxicity. 
These results suggest that this peptide (RLSALESRV) is a 
novel HLA-A*02:01-restricted CTL epitope and that it may 
be a new target for antigen-specific immunotherapy against 
EML4-ALK-positive cancers.
Introduction
Lung cancer is one of the main causes of cancer-related 
mortality. Approximately 85% of lung cancers are diagnosed 
as non-small cell lung cancer (NSCLC), and the overall 
survival (OS) rate for advanced NSCLC is poor. The 5-year 
survival rate is 5% for stage IIIb NSCLC and <1% for stage IV 
NSCLC (1). Treatment for NCSLC is determined by the 
patient's clinical and tumor characteristics, performance status 
(PS), the histological subtype and tumor genotype/phenotype.
Recently, there have been many studies concerning 
agents that target molecular changes, such as mutations 
in the epidermal growth factor receptor (EGFR) and the 
fusion oncogene EML4-ALK, in which the echinoderm 
microtubule-associated protein-like 4 (EML4) is fused with 
the intracellular domain of anaplastic kinase (ALK) (2-4). 
Although significant advances have been made in the treat-
ment of NSCLC using molecular targeted therapies such 
as erlotinib and crizotinib, the median OS for patients with 
advanced NSCLC remains low (5,6), and acquired resistance 
to target agents is a major clinical problem. Therefore, the 
development of novel therapies is needed (7).
Immunotherapy manipulates the immune system to control 
and eradicate cancer. Many recent studies provide evidence 
suggesting that immunotherapeutic manipulations are viable 
in many tumor types, including lung cancer. Numerous trials 
of peptide vaccines, autologous cellular therapy, T cell-directed 
antibody therapy and monoclonal antibody therapy for lung 
cancer have been carried out around the world (8-10) and some 
of them have shown favorable results (11-13).
The EML4-ALK fusion gene was identified in NSCLC 
patients by a team led by Professor H. Mano. This fusion 
gene was formed as the result of a small inversion within the 
short arm of chromosome 2 that joins differing portions of 
the EML4 gene with a portion of the ALK gene (14,15). As 
a result of this fusion, constant dimerization of the kinase 
domain of ALK is induced and its catalytic activity increases 
consequently.
The EML4-ALK fusion gene is mainly identified in young, 
never/former light smokers with NSCLC (16). It is estimated 
that approximately 5% of all NSCLC cases have this fusion 
gene. A few reports have also identified EML4-ALK in other 
cancers, namely breast cancer and colorectal cancer (17,18). 
For the most part, the EML4-ALK fusion gene and other 
mutations, such as those in EGFR and KRAS, are mutually 
exclusive (19).
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The chromosomal inversion does not always occur in the 
same location, and multiple EML4-ALK variants have been 
identified (19). At least 11 variants have been reported. The 
most common variants are E13;A20 (variant 1) and E6a/b;A20 
(variant 3a/b), which have been detected in 33% and 29% of 
NSCLC patients, respectively (14).
PF-02341066 (crizotinib) is an ALK inhibitor currently 
under clinical development. Kwak et al conducted an 
open-label, multi-center, two-part phase I trial and found a 
remarkable 57% overall response rate and a 72% 6-month 
progression-free survival rate (20).
In spite of the marked antitumor activity of crizotinib, 
ALK-positive cancers invariably gain resistance to crizotinib. 
In the case of ALK-positive cancers, as well as EGFR-mutant 
lung cancer, resistance develops on average within the first 
2 years of therapy (21). The main resistance mutations are 
L1196M, a gatekeeper mutation and C1156M. In addition 
to ALK mutations, other known mechanisms for acquired 
resistance include ALK amplification (21,22) and EGFR acti-
vation (23,24). To overcome resistance, new ALK inhibitors 
are currently in early phase studies (25). Novel combinato-
rial strategies to overcome crizotinib resistance and further 
improve the clinical outcome are needed.
We focused on this new fusion array as a novel target 
of immunotherapy. There are several methods to detect 
EML4-ALK NSCLC, including polymerase chain reaction 
(PCR), immunohistochemistry (IHC) and fluorescence in situ 
hybridization (FISH) (19). These methods detect high-level 
EML4-ALK fusion gene expression. Passoni et al identi-
fied two HLA-A*02:01-restricted ALK-derived peptides that 
induce peptide-specific CTL lines (26).
We focused on the EML4 array as a novel epitope of 
immunotherapy. We identified a candidate 9- or 10-amino 
acid array of novel epitopes using the Bioinformatics and 
Molecular Analysis Section (BIMAS) software and analyzed 
its potential as a new immunotherapy epitope, with respect 
to its ability to induce anticancer activity. We then induced 
and generated a peptide-specific CTL clone from peripheral 
blood lymphocytes of HLA-A*02:01-positive healthy donors. 
We report here that an EML4-ALK-derived peptide-specific 
human CTL clone recognized peptide-pulsed T2 cells and 
HLA-A*02:01-positive and EML4-ALK-positive tumor cells 
pretreated with IFN-γ. Furthermore, we showed that immu-
notherapy with this novel epitope peptide has potential for 
treatment of EML4-ALK-positive NSCLC.
Materials and methods
Peptides. Human EML4-ALK-derived peptides carrying 
binding motifs for HLA-A*02:01-/HLA-A*24:02-encoded 
molecules were identified by HLA-peptide binding predic-
tions using the BIMAS program (http://bimas.dcrt.nih.
gov/molbio/hla_bind/index.html). We purchased a total of 
seven EML4-ALK-derived peptides carrying HLA-A*02:01 
binding motifs and two peptides carrying HLA-A*24:02 
binding motifs from Geneworld (Tokyo, Japan).
Cell lines. The H2228 human lung adenocarcinoma cell line 
and EML4-ALK fusion protein variant 3 (E6;A20) were 
kindly provided by Professor S. Yano (Kanazawa University).
T2 is a lymphoblastoid cell line that lacks TAP function 
and has HLA-A*02:01 molecules that can easily be loaded 
with exogenous peptides. T2A24 is the same cell line but with 
HLA-A*24:02 instead. T2 and T2A24 cells were cultured in 
RPMI medium supplemented with 10% heat-inactivated FBS.
HLA-A*02:01/HLA-A*24:02 binding assay. In order to 
determine the binding ability of the predicted peptides to 
HLA-A*02:01/HLA-A*24:02 molecules, an in vitro cellular 
binding assay was performed as reported previously (27).
Briefly, after incubation of the T2/T2A24 cells in culture 
medium at 26˚C for 18 h, cells were washed with PBS 
and suspended in 1 ml Opti-MEM (Invitrogen, Carlsbad, 
CA, USA) with or without 100 µg peptide and then incu-
bated at 26˚C for 3 h and at 37˚C for 3 h. After washing 
with PBS, HLA-A*02:01/HLA-A*24:02 expression was 
measured by flow cytometry using a FITC-conjugated and 
HLA-A*02:01-/HLA-A*24:02-specific monoclonal antibody 
(mAb) and the mean fluorescence intensity was recorded.
Generation of dendritic cells. CD14+ cells were isolated 
from human peripheral blood mononuclear cells (PBMCs) 
using human CD14 microbeads (Miltenyi Biotec, Bergisch 
Gladbach, Germany). Immature dendritic cells (DCs) were 
generated from CD14+ cells using interleukin (IL)-4 (10 ng/ml; 
PeproTech Inc., Rocky Hill, NJ, USA) and granulocyte-
macrophage colony-stimulating factor (GM-CSF; 10 ng/ml; 
PeproTech) in RPMI-1640 medium supplemented with 10% 
FBS. Maturation of DCs was induced by prostaglandin E2 
(PGE2; 1 µg/ml; Sigma, St. Louis, MO, USA) and tumor 
necrosis factor (TNF-)-α (10 ng/ml; PeproTech).
Induction of EML4-ALK-derived peptide-specific CTLs 
from PBMCs. CD8+ cells were isolated from PBMCs 
using human CD8 microbeads (Miltenyi Biotec, Bergisch 
Gladbach, Germany). CD8+ cells (2x106) were stimulated by 
peptide-pulsed irradiated autologous mature DCs (1x105). 
Autologous DCs were prepared from a limited supply; 
artificial antigen presenting cells (aAPCs) (K562/A2 or 
A24/CD80/CD83) were alternatively used for further examina-
tion. After 1 week, these cells were stimulated twice per week 
by peptide-pulsed irradiated artificial APC-A2 or artificial 
APC-A24 cells (1x105). Supplementation with 10 IU/ml IL-2 
(Proleukin; Novartis Pharmaceuticals, Basel, Switzerland) and 
10 ng/ml IL-15 (PeproTech) was performed every 3 to 4 days 
between stimulations (28).
IFN-γ ELISPOT assay. Specific secretion of IFN-γ from 
human CTLs in response to stimulator cells was assayed 
using the IFN-γ ELISPOT kit (BD Biosciences), according to 
the manufacturer's instructions. Stimulator cells were pulsed 
with peptide for 2 h at room temperature and then washed. 
Responder cells were incubated with stimulator cells for 
20 h. The resulting spots were counted using an ELIPHOTO 
counter (Minerva Tech, Tokyo, Japan). HIV-gag (77-85) 
(SLYNTYATL) was used as an irrelevant peptide in the CTL 
assay.
Generation of CTL clones. Cultured cells were incubated 
with peptide-pulsed T2/T2A24 cells at a ratio of 2:1 for 3.5 h 
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at 37˚C. CD107a-specific antibodies (BioLegend, San Diego, 
CA, USA) were included in the mixture during the incubation 
period. CD8+CD107a+ cells were sorted using a FACSAria II 
cell sorter (BD Biosciences). Sorted CTLs were stimulated 
and the CTL clones were established as described previ-
ously (29).
Flow cytometry. H2228 cells with or without pretreat-
ment with 100 U/ml IFN-γ (PeproTech) for 48 h were 
harvested and stained with anti-HLA-A2 Ab-FITC (MBL, 
Japan) and analyzed using a FACSCanto II flow cytometer 
(BD Biosciences). Flow cytometry data were analyzed using 
FlowJo software.
Cytotoxicity assay. The cytotoxic capacity was analyzed 
using the Terascan VPC system (Minerva Tech, Tokyo). The 
CTL clone was used as the effector cell type. Target cells 
treated with 100 U/ml IFN-γ (PeproTech) 42 h previously 
were labeled through incubation in calcein-AM solution 
for 30 min at 37˚C. The labeled cells (1x104) were then 
co-cultured with the effector cells for 4-6 h. Fluorescence 
intensity was measured before and after the culture period, 
and specific cytotoxic activity was calculated as described 
previously (29).
HLA-A*02:01 blocking of T-cell activity was tested 
by pre-incubating the target cells with anti-HLA-A, -B, 
-C mAb (W6/32) or an isotype control mAb (mIgG2a,κ; 
BioLegend San Diego, CA, USA).
Results
Identification of HLA-A*02:01-/HLA-A*24:02-restricted 
EML4-ALK-derived peptides. As candidate EML4-ALK- 
derived and HLA-A*02:01-/HLA-A*24:02-restricted CTL 
epitopes, we selected nine peptides with highly predicted 
scores for HLA-A*02:01/HLA-A*24:02 binding calculated 
using BIMAS software (Tables I and II) and evaluated their 
ability to bind to HLA-A*02:01/HLA-A*24:02 molecules. All 
nine peptides were able to bind HLA-A*02:01/HLA-A*24:02 
molecules (Fig. 1).
Generation of an EML4-ALK-derived peptide-specific 
CTL clone from human PBMCs. We next assessed the 
capacity of EML4-ALK-derived peptides to generate 
peptide-specific CTLs in vitro from human PBMCs of 
HLA-A*02:01/HLA-A*24:02 healthy donors. CTLs were 
induced by three stimulations with DCs or artificial APCs 
loaded with the EML4-ALK-derived peptides. CTLs were 
tested for specificity for each peptide using the IFN-γ ELISPOT 
assay. Peptides A, B and C could induce peptide-specific 
CTLs that were able to specifically recognize T2 cells pulsed 
with each peptide, but not T2 cells without peptides (Fig. 2). 
Peptides B and C were able to induce CTLs from only one 
donor (healthy donor 3 for peptide B and healthy donor 4 for 
Table I. HLA-A2 peptide binding predictions of the BIMAS 
program.
Peptide name Peptide sequence Binding scorea
A RLSALESRV 69.552
B AISEDHVASV 90.183
C TVLKAALADV 51.79
D KLIPKVTKT  59.989
E YLLPTGEIV 237.82
F MLIWSKTTV 118.238
G VMLIWSKTTV 315.95
aBinding scores were estimated using BIMAS software (http://www-
bimas.cit.nih.gov/mobio/hla_bind/). 
Table II. HLA-A24 peptide binding predictions of the BIMAS 
program.
Peptide name Peptide sequence Binding scorea
H NYDDIRTEL 369.6
I VYFIASVVVL 200
aBinding scores were estimated using BIMAS software (http://www-
bimas.cit.nih.gov/mobio/hla_bind/). 
Figure 1. EML4-ALK-derived peptides bound to HLA-A2 or HLA-A24 
molecules. In vitro cellular peptide binding assays for HLA-A*02:01 (A) or 
HLA-A*24:02 (B) were performed using a FACS system.
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peptide C), but peptide A was able to induce CTLs in three of 
four donors (healthy donors 2, 3 and 4). Based on this result, 
we used peptide A for further examinations.
Next, we obtained one CTL clone from peptide A-specific 
CTLs that was able to specifically recognize T2 cells pulsed 
with peptide A, but not T2 cells pulsed with an irrelevant 
HIV-gag peptide, using single cell sorting with a CD107a 
antibody. The population of CD8+CD107a+ cells represented 
0.984% of all stimulated cells (Fig. 3A). These cells were sorted 
as single cells in each well of a 96-well plate. Twenty-one days 
after cell sorting, peptide specificity was assessed using the 
IFN-γ ELISPOT assay (Fig. 3B). The established clone reacted 
to the T2 cells pulsed with peptide A, but not to T2 cells pulsed 
with the irrelevant HIV-gag peptide. These results indicate that 
a peptide A-specific CTL clone was successfully established 
from PBMCs from a healthy donor.
The EML4-ALK-specific CTL clone recognizes HLA-A*02:01+ 
lung carcinoma cells with the EML4-ALK variant 3a/b 
incubated with IFN-γ. We next evaluated the ability of the 
EML4-ALK-specific CTL clone to recognize the cancer cell 
line H2228, which expresses HLA-A*02:01 and EML4-ALK, 
using the IFN-γ ELISPOT assay. Even though the EML4-ALK-
specific CTL clone failed to recognize H2228 cells, it did 
recognize those pretreated with 100 U/ml IFN-γ 48 h prior 
to examination (Fig. 4A). We examined the effect of IFN-γ 
on H2228 cells. Incubating target cells with IFN-γ for 48 h 
increased the expression of MHC class I molecules on the 
cell surface (Fig. 4B). This result indicates that the peptide 
A-specific CTL clone was able to recognize H2228 cells 
because of increased expression of MHC-class I on the H2228 
cell surface.
Figure 2. IFN-γ release by in vitro-induced anti-EML4-ALK CTLs. CD8+ T cells from four healthy donors were stimulated with EML4-ALK-derived 
peptide-pulsed autologous DCs and aAPCs. CTLs induced by EML4-ALK-derived peptides (1x105) were stimulated with T2 cells pulsed with or without 1 µM 
EML4-ALK-derived peptides. IFN-γ-producing CTLs were detected by IFN-γ ELISPOT assay. DCs, dendritic cells; aAPCs, artificial antigen presenting 
cells; CTLs, cytotoxic T cells.
Figure 3. Peptide A-specific CTL clone established from anti-EML4-ALK 
CTL. (A) Peptide A-specific CTL clones established using CD107a single 
cell sorting. Peptide A-specific CTLs (1x105) were incubated with peptide-
pulsed T2 cells (5x104) with CD107a-specific antibodies for 3.5 h at 37˚C. 
CD8+CD107a+ cells were sorted using a FACSAria II cell sorter. Square, 
CD8+CD107a+ cells that are peptide A-specific CTL clones. (B) Recognition 
of peptide-pulsed T2 cells by peptide A-specific CTL clones. A pep-
tide A-specific CTL clone (1x104 cells) was incubated with stimulator cells 
that had been pulsed with 1 µM peptide A or HIV-gag peptide. IFN-γ-
producing CTLs were detected by IFN-γ ELISPOT assay. CTLs, cytotoxic 
T cells.
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Specific IFN-γ production by the peptide A-specific CTL 
clone was detectable in H2228 cells treated with IFN-γ. The 
specificity was abolished by an anti-HLA-class I mAb, but not 
by an isotype control, suggesting that the observed production 
was HLA-A2 restricted (Fig. 4C).
A cytotoxicity assay was also performed. The peptide A- 
specific CTL clone was able to specifically lyse H2228 cells 
pretreated with IFN-γ 48 h prior to examination. This specific 
lysis was blocked by the anti-HLA-class I mAb, but not by 
the isotype control. These results indicate that the peptide 
A-specific CTL clone showed cytotoxicity and the ability to 
produce IFN-γ against HLA-A*02:01+ EML4-ALK+ NSCLC 
cell lines (Fig. 5).
Discussion
In the present study, we identified a new tumor-associated 
CTL epitope (peptide A) derived from EML4-ALK, which 
binds to HLA-A*02:01 molecules, and we were able to estab-
lish a peptide-specific CTL clone from human PBMCs that 
specifically recognized cognate peptide-pulsed T2 cells and 
HLA-A*02:01 tumor cells expressing EML4-ALK that had 
been pretreated with IFN-γ.
EML4-ALK-positive lung cancers are highly sensitive 
to ALK inhibition. However, as with trastuzumab or gefi-
tinib (30,31), patients typically gain resistance within 1 to 2 
years of starting therapy (23). We aimed to overcome these 
difficulties with immunotherapy.
We identified a glypican-3 (GPC3)-derived peptide and 
showed that GPC3-specific CTL frequency after vaccination 
correlated with OS. OS was significantly longer in patients 
with high GPC3-specific CTL frequencies than in those 
Figure 4. Recognition of lung carcinoma cells expressing HLA-A*02:01 and the EML4-ALK fusion gene by the peptide A-specific CTL clone. The peptide 
A-specific CTL clone recognized H2228 cells pretreated with IFN-γ 48 h prior to the assay. (A) The peptide A-specific CTL clone (1x104 cells) was incubated 
with H2228 cells with or without IFN-γ. IFN-γ production was detected by IFN-γ ELISPOT assay. (B) IFN-γ increased expression of HLA-A2 presented 
on H2228 cells. Incubation of H2228 cells with 100 U/ml IFN-γ for 48 h increased HLA-A2 presentation on the cells. Dotted line, HLA-A2 on H2228 cells 
without IFN-γ. Black line, HLA-A2 on H2228 cells incubated with IFN-γ (higher than on H2228 cells without IFN-γ). Dashed line and shaded region: 
no staining of H2228 cells with/without IFN-γ. (C) Inhibition of IFN-γ production by an anti-HLA-class I mAb. Blocking experiments were performed 
using an HLA-A, -B, -C-specific mAb (W6/32) or an isotype control mAb (mIgG2a,κ). The peptide A-specific CTL clone was incubated with H2228 cells 
(HLA-A*02:01+/EML4-ALK+) pretreated with IFN-γ 48 h prior to examination. IFN-γ-producing CTL clones were detected by IFN-γ ELISPOT assay. The 
bar graph shows the percentage of inhibition. CTL, cytotoxic T cell.
Figure 5. Cytotoxic activity of the peptide A-specific CTL clone against 
H2228 cells. The peptide A-specific CTL clone was incubated with H2228 
cells pretreated with IFN-γ 48 h prior to the assay at various E/T ratios, 
and specific lysis was assessed. Blocking experiments were performed 
using the HLA-A, -B, -C-specific mAb (W6/32) or the isotype control mAb 
(mIgG2a,κ). CTL, cytotoxic T cell.
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with low frequencies (32). This indicates that the ability to 
induce a peptide-specific CTL clone is important for effective 
immunotherapy. We also revealed that GPC3 is an ideal target 
for anticancer immunotherapy since it is specifically overex-
pressed in hepatocellular carcinoma (HCC) (33-35).
In the present study, we chose a peptide array from 
EML4-ALK, from which we were able to induce a peptide-
specific CTL clone. EML4-ALK is a strong oncogene 
overexpressed in cancer cells of NSCLC, breast cancer, 
kidney cancer and colon cancer (17). We performed RT-PCR 
and assayed the EML4 DNA levels of certain lung cancer cell 
lines. H2228 cells express EML4 moderately but at higher 
levels than other lung cancer cell lines. EML4 expression has 
been reported as highly expressed in CD8+ T cells. RT-PCR 
showed that EML4 DNA levels were high in PBMCs and CD8+ 
T cells. Because of a lack of suitable antibodies, we could not 
perform western blotting. However, our success at inducing a 
peptide A-specific CTL clone from CD8+ T cells indicated that 
the CTL clone had no cytotoxicity against CD8+ T cells.
This CTL clone could not recognize cancer cell lines 
without the ability to increase the amount of HLA class I 
presented on cell surfaces. Further examination is needed to 
achieve higher tumor reactivity. Combination chemotherapy or 
radiation therapy plus immunotherapy was recently reported 
to have a synergistic effect (36). Moreover, some mecha-
nisms of synergy between radiation therapy, chemotherapy 
and immunotherapy have been revealed (37). In one of the 
mechanisms, these therapies upregulated tumor antigens and 
MHC moieties. These results suggest that combination therapy 
could be used to make tumor cell lines more susceptible to this 
peptide A-specific CTL clone-mediated cytolysis (38-41).
In addition, this treatment may be able to overcome resis-
tance to ALK inhibition. Some resistance mechanisms for 
targeting drugs have been examined. The most commonly 
identified causes of resistance are point mutations such as 
L1196M (42-44), G1269A (22) and S1206Y (21). These point 
mutations occur in the tyrosine kinase domain, which plays an 
important role in oncogenesis. Our peptide array was selected 
from EML4, which has no correlation with these point muta-
tions. It is possible that this treatment is effective for tumor 
cells resistant to ALK inhibitors.
In this study, we identified a new epitope peptide derived 
from the EML4-ALK fusion gene. We successfully induced 
an HLA-A*02:01-restricted peptide-specific CTL clone that 
demonstrated cytotoxicity for EML4-ALK-positive tumor 
cells. This is a new epitope-based vaccine therapy design for 
EML4-ALK-positive cancer cells. In order to obtain a stronger 
effect, further analysis is needed.
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